CN Patent

CN118717992B — 补体因子c3作为结晶样视网膜色素变性治疗靶点的应用

Assigned to Huazhong University of Science and Technology · Expires 2025-01-28 · 1y expired

What this patent protects

本发明属于眼科疾病治疗技术领域，尤其涉及补体因子C3作为结晶样视网膜色素变性治疗靶点的应用。本发明首次提出补体因子C3作为结晶样视网膜色素变性的治疗靶点，通过抑制补体因子C3的功能，可显著改善结晶样视网膜色素变性细胞和斑马鱼模型的脂质代谢紊乱的情况，减缓脂滴的累积，为治疗结晶样视网膜色素变性提供了有利证据。而且本发明的治疗方法简单，成本较低，与基因疗法和细胞治疗等相比具有显著优势。

USPTO Abstract

本发明属于眼科疾病治疗技术领域，尤其涉及补体因子C3作为结晶样视网膜色素变性治疗靶点的应用。本发明首次提出补体因子C3作为结晶样视网膜色素变性的治疗靶点，通过抑制补体因子C3的功能，可显著改善结晶样视网膜色素变性细胞和斑马鱼模型的脂质代谢紊乱的情况，减缓脂滴的累积，为治疗结晶样视网膜色素变性提供了有利证据。而且本发明的治疗方法简单，成本较低，与基因疗法和细胞治疗等相比具有显著优势。

Drugs covered by this patent

Patent Metadata

Patent number
CN118717992B
Jurisdiction
CN
Classification
—
Expires
2025-01-28
Drug substance claim
No
Drug product claim
No
Assignee
Huazhong University of Science and Technology
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.